Cocrystal Pharma Inc (COCP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $18.88M
Last updated: Nov 17, 2026 at 4:10 PM ET
Cocrystal Pharma Inc (COCP) Statistics
Cocrystal Pharma (COCP) has a market cap of $18.88M and an enterprise value of $14.01M. It kept -2605.29% of revenue as net income over the last 12 months. Its share count is up 58.48% from a year earlier.
Total Valuation
Enterprise value is 25.81% below the market cap, as cash exceeds debt.
| Market Cap | $18.88M |
|---|---|
| Enterprise Value | $14.01M |
| Latest price (Nov 17, 2026) | $1.01 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 40.4x and 6.6x. Its year-end P/S ranged from 2.4x to 151.1x from 2019 to 2024.
| P/S Ratio | 40.4x |
|---|---|
| Forward P/S | 0.2x |
| P/B Ratio | 6.6x |
Price Statistics
The stock is down 1.94% over 52 weeks and trades 5.61% below its 50-day average.
| Beta (1Y) | 1.25 |
|---|---|
| 52-Week Change | -1.94% |
| 1-Month Change | +6.70% |
| 3-Month Change | -11.79% |
| 6-Month Change | -12.17% |
| 5-Year Change | -90.71% |
| 10-Year Change | -99.42% |
| Total Return (1Y) | -1.94% |
| Total Return (3Y CAGR) | -15.76% |
| Total Return (5Y CAGR) | -36.81% |
| Return vs SPY (1Y) | -12.54% |
| Max Drawdown (1Y) | -47.77% |
| Max Drawdown (3Y) | -74.77% |
| Sharpe Ratio (1Y) | -0.01 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $1.07 |
| 200-Day Average | $1.10 |
| 52-Week Range | $0.76 to $2.03 |
| RSI (14 Days) | 48.1 |
| Average Volume (20 Days) | 29.29K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.72x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.72x |
|---|---|
| Quick Ratio | 1.72x |
| Debt / Equity | 0.00x |
| Interest Coverage | 121.56x |
Returns and Efficiency
Return on equity is -423.66% and return on assets is -167.33% over the last 12 months.
| Return on Equity (ROE) | -423.66% |
|---|---|
| Return on Assets (ROA) | -167.33% |
| ROA (5Y Average) | -78.30% |
| Asset Turnover | 0.05x |
Scores
COCP has an Altman Z-Score of -75.10, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -75.10 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $435.00K over the last 12 months is up 219.85% from the 12 months before.
| Revenue | $435.00K |
|---|---|
| Revenue Growth (YoY) | +219.85% |
| Gross Profit | $1.83M |
| Operating Income | -$11.51M |
| Pretax Income | -$11.33M |
| Net Income | -$11.33M |
| Reported EPS (TTM) | -$0.77 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 39.44% of the $6.77M in total assets.
| Cash and Equivalents | $4.87M |
|---|---|
| Total Debt | $0 |
| Net Cash | $4.87M |
| Net Cash Per Share | $0.28 |
| Working Capital | $2.31M |
| Shareholder Equity | $2.67M |
| Book Value Per Share | $0.15 |
| Total Assets | $6.77M |
| Total Liabilities | $4.10M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$8.89M |
|---|---|
| FCF Per Share | -$0.46 |
| Depreciation and Amortization | $47.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2645.98%.
| Gross Margin | 420.46% |
|---|---|
| Operating Margin | -2645.98% |
| Pretax Margin | -2605.29% |
| Net Margin | -2605.29% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -53.50% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -53.50% |
Dividends and Yields
COCP does not pay a dividend.
| Buyback Yield | -5.87% |
|---|---|
| Shareholder Yield | -5.87% |
Stock Splits
The last split was a 1-for-12 reverse split on Oct 11, 2022.
| Last Split Date | Oct 11, 2022 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:12 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About COCP
What is COCP's market cap?
Cocrystal Pharma has a market cap of $18.88M. Its enterprise value, which adds debt and subtracts cash, is $14.01M.
How many shares of COCP are outstanding?
Cocrystal Pharma has 17.42M shares outstanding. The count is up 58.48% from a year earlier.
Does COCP pay a dividend?
No. Cocrystal Pharma does not pay a dividend.
How much debt does COCP have?
Cocrystal Pharma has $0 of total debt and $4.87M of cash and equivalents, a net cash position of $4.87M.
COCP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts